Skip to content
You can now search across every topic, entity and event.What's new
Pandemics and Biosecurity
9JUN

FAO costs drug-resistance inaction at $318bn

2 min read
09:58UTC

The FAO put a price on antimicrobial resistance on 3 June, projecting $318bn in cumulative livestock losses by 2040, about six times the cost of acting now.

ScienceDeveloping
Key takeaway

Pricing drug resistance as $318bn in lost production reaches ministries a death toll never moved.

The Food and Agriculture Organization (FAO), the UN's Rome-based agency for food and farming, put a price on inaction over AMR (antimicrobial resistance, the process by which bacteria stop responding to the drugs meant to kill them) on 3 June. Its report projects global antimicrobial use in livestock rising 30% by 2040 against a 2019 baseline, and cumulative livestock production losses reaching $318bn by 2040 under a high-resistance scenario 1. That $318bn runs about six times the cost of acting now.

May's adoption of the WHO Global Action Plan on AMR set a mortality target, a 10% cut in bacterial AMR deaths by 2030. FAO has now attached a balance-sheet figure to the alternative, routing the same problem through food-security economics to reach an audience that a death toll did not. The 6:1 inaction-to-action ratio is the lever, reframing mitigation spending as loss avoidance rather than public-health cost.

Cheap antibiotics keep crowded herds productive, so use climbs with demand for meat, and resistance follows the use, an unremarkable chain that the $318bn figure now prices. Pricing the loss in production rather than deaths is how the issue reaches the agriculture and finance ministries that control the antibiotics and that a public-health framing never reached.

Deep Analysis

In plain English

Farmers use antibiotics to keep livestock healthy and speed up animal growth. When antibiotics are used too frequently, bacteria evolve to resist them, making those drugs less effective for both animals and humans over time. This is called antimicrobial resistance, or AMR. FAO, the UN's food and agriculture body, published a report on 3 June estimating that unchecked AMR will cost the farming industry $318 billion in lost livestock production by 2040, as animals die from infections that should be treatable. Preventing that outcome would cost around one-sixth as much. The report argues that tackling antibiotic overuse in farming serves both economic and public health goals.

Deep Analysis
Root Causes

The projected 30% rise in livestock antimicrobial use to 2040 reflects a structural dependency: antibiotic prophylaxis compensates for suboptimal biosecurity in intensive production systems. The economic incentive structure rewards volume and speed of production over herd health investment, particularly in markets where veterinary drug regulation is weak or enforcement is absent.

The WHO GAP-AMR 2026-2036, adopted 23 May, sets a 10% reduction target in AMR-attributable deaths by 2030 , a human-health metric. The FAO report reframes AMR as a food-security and economic threat independent of that metric, addressing a different political constituency: agriculture ministries and development finance institutions that do not engage with WHO's public-health framing.

What could happen next?
  • Consequence

    FAO's $318bn figure provides an economic mandate for agriculture ministries to engage with the WHO GAP-AMR 2026-2036 (ID:3599) framework , translating a public-health target into a production-economics argument that reaches beyond health ministry budgets.

  • Risk

    The 30% projected rise in livestock antimicrobial use by 2040 is concentrated in regions with limited veterinary drug regulatory capacity, meaning the economic cost will fall disproportionately on small-scale farmers in lower-income countries who have the least ability to absorb it.

Sources:FAO
First Reported In

Update #6 · Ebola outbreak gets an R0, and a fork

FAO· 9 Jun 2026
Read original
Different Perspectives
UK Health Security Agency
UK Health Security Agency
UKHSA said egg consumption remains the strongest signal in its 207-case Salmonella Enteritidis investigation. The genomic cluster and 38% hospitalisation among people with available information make exposure identification a public-health priority.
GLEWS+
GLEWS+
GLEWS+ assessed spillover risk from clade B MERS in Nile Basin camels as high if the clade establishes, while rating evidence for spread in camel populations low confidence. The joint assessment makes whole-genome sequencing the next test of the threat.
WHO Regional Office for Africa
WHO Regional Office for Africa
WHO's Africa office said transmission in DR Congo is outpacing control efforts after laboratory capacity reached 19 sites and treatment capacity exceeded 1,300 beds. The assessment puts access, insecurity, community deaths and late care-seeking ahead of a simple equipment shortage.
People in Guatemala
People in Guatemala
Guatemala's population now carries the region's largest reported measles burden, with 30,371 confirmed cases and 26 deaths. The scale shifts practical attention from the Mexico-centred frame that followed the World Cup's travel consequences.
Pan American Health Organization
Pan American Health Organization
PAHO rated regional measles risk very high after recording 47,459 confirmed cases and 44 deaths through week 28. It names vaccination coverage, accumulated susceptibles and mass gatherings with broad international participation as general risk factors.
Chinese health authorities
Chinese health authorities
China reported three human H9N2 cases to WHO between 10 and 16 July: two four-year-olds recovered, a 44-year-old man remains in intensive care, the first severity signal in a cluster that has produced 173 cases and 2 deaths globally since 2015. The subtype is distinct from the H5N1 series this topic otherwise tracks.